LJM716
Total Payments
$159,997
Transactions
9
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2,627 | 1 | 0 |
| 2019 | $318.50 | 1 | 0 |
| 2018 | $15,187 | 2 | 1 |
| 2017 | $141,865 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $159,872 | 8 | 99.9% |
| Food and Beverage | $125.00 | 1 | 0.1% |
Payments by Type
Research
$159,872
8 transactions
General
$125.00
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I OPEN LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF LJM716 PLUS BYL719 AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 PLUS BREAST CANCER | Novartis Pharmaceuticals Corporation | $85,207 | 0 |
| A PHASE IB AND OR II OPEN LABEL STUDY OF LJM716 IN COMBINATION WITH BYL719 COMPARED TO TAXANE OR IRINOTECAN IN PATIENTS WITH PREVIOUSLY TREATED ESOPHEAGEAL SQUAMOUS CELL CARCINOMA | Novartis Pharmaceuticals Corporation | $71,665 | 0 |
| A MULTICENTER OPEN LABEL DOSE ESCALATION PHASE I STUDY OF LJM716 ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH HER2 OVEREXPRESSING METASTATIC BREAST CANCER OR GASTRIC CANCER | Novartis Pharmaceuticals Corporation | $3,000 | 0 |
Top Doctors Receiving Payments for LJM716
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $159,872 | 8 |
| , MD | Gastroenterology | Kailua, HI | $125.00 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $159,997
Product Information
- Type Drug
- Total Payments $159,997
- Total Doctors 1
- Transactions 9
About LJM716
LJM716 is a drug associated with $159,997 in payments to 1 healthcare providers, recorded across 9 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $2,627 was paid across 1 transactions to 0 doctors.
The most common payment nature for LJM716 is "Unspecified" ($159,872, 99.9% of total).
LJM716 is associated with 3 research studies, including "A PHASE I OPEN LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF LJM716 PLUS BYL719 AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 PLUS BREAST CANCER" ($85,207).